Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Industry: Biotechnology
F
Biotech is Zen Rated F and is the 139th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Financials
Market Cap
ROE
ROA
ROCE
ROIC
D/E
Current Ratio
Gross Margin
Profit Margin
Operating Margin
XCUR
EXICURE INC
$53.32M-319.70%-82.40%-80.73%-88.70%1.224.45100.00%-1,940.20%-1,935.00%
XLO
XILIO THERAPEUTICS INC
$38.93M-238.30%-73.20%-132.93%1,397.00%3.042.21100.00%-918.00%-918.05%
PTGX
PROTAGONIST THERAPEUTICS INC
$2.84B47.70%42.50%40.07%65.90%0.1012.48100.00%63.30%64.32%
TCRX
TSCAN THERAPEUTICS INC
$81.49M-60.10%-38.20%-36.95%-57.90%0.548.14100.00%-4,527.70%-4,397.94%
EVAX
EVAXION BIOTECH A
$1.84MN/A-83.30%-101.42%-70.50%-8.562.01100.00%-316.00%-246.17%
VALN
VALNEVA SE
$551.34M-6.50%-2.50%3.24%3.00%1.762.6141.90%-7.20%7.37%
LXRX
LEXICON PHARMACEUTICALS INC
$184.36M-93.90%-56.80%-73.00%-58.20%1.055.4498.00%-644.80%-594.65%
SEER
SEER INC
$117.77M-24.40%-21.90%-24.63%-23.70%0.1216.5349.80%-611.10%-610.45%
MDWD
MEDIWOUND LTD
$184.56M-113.60%-45.10%-36.95%-68.00%1.361.9713.00%-149.50%-85.81%
YMAB
Y-MABS THERAPEUTICS INC
$212.07M-31.30%-23.40%-32.43%-120.10%0.304.1682.60%-33.80%-35.58%
LENZ
LENZ THERAPEUTICS INC
$656.07M-24.60%-23.20%-24.29%-42.30%0.0620.37N/AN/AN/A
VRNA
VERONA PHARMA PLC
$5.01B-95.20%-43.90%-32.34%-72.30%1.3210.6393.90%-410.20%-330.16%
CYTK
CYTOKINETICS INC
$4.67BN/A-45.60%-45.16%-30.00%-11.356.17100.00%-3,191.10%-2,987.04%
RLAY
RELAY THERAPEUTICS INC
$456.01M-44.40%-39.60%-41.16%-47.30%0.1215.95100.00%-3,374.70%-3,374.72%
IMTX
IMMATICS NV
$517.80M3.50%2.40%3.40%6.10%0.219.26100.00%9.80%13.70%
ALEC
ALECTOR INC
$91.16M-82.80%-21.70%-34.65%-30.40%2.693.40100.00%-118.40%-118.26%
PHIO
PHIO PHARMACEUTICALS CORP
$13.04M-150.20%-120.40%-151.39%986.50%0.225.65N/AN/AN/A
ATYR
ATYR PHARMA INC
$275.46M-85.00%-62.80%-78.21%-71.60%0.395.48100.00%-27,243.80%-27,243.83%
CUPR
CUPRINA HOLDINGS (CAYMAN) LTD
N/AN/A-91.30%35.77%44.70%-1.470.3035.70%-1,412.10%-1,317.46%
TRDA
ENTRADA THERAPEUTICS INC
$305.64M16.90%12.10%13.66%16.60%0.2311.15100.00%31.10%31.54%
TRAW
TRAWS PHARMA INC
$10.05MN/A-309.10%-407.13%767.90%-1.792.16100.00%-24,192.00%-24,192.04%
ZYME
ZYMEWORKS INC
$802.22M-31.70%-24.30%-31.11%-34.00%0.373.40100.00%-160.80%-152.82%
IPSC
CENTURY THERAPEUTICS INC
$46.81M-66.90%-33.60%-55.84%-41.70%1.191.50100.00%-1,920.90%-1,893.70%
RGNX
REGENXBIO INC
$297.51M-69.90%-41.60%-59.11%-47.30%0.802.6959.70%-272.50%-257.35%
CAPR
CAPRICOR THERAPEUTICS INC
$513.86M-66.40%-46.10%-27.08%-94.50%0.177.77100.00%-181.70%-181.71%
ERAS
ERASCA INC
$328.59M-40.10%-33.60%-34.31%-39.50%0.199.84N/AN/AN/A
RARE
ULTRAGENYX PHARMACEUTICAL INC
$3.30B-196.10%-38.20%-48.96%-70.90%5.002.3786.30%-101.60%-101.31%
RYTM
RHYTHM PHARMACEUTICALS INC
$3.90B-790.50%-75.80%-86.59%-135.40%10.483.2489.70%-203.30%-184.17%
FTRE
FORTREA HOLDINGS INC
$476.10M-22.20%-8.70%-7.92%-12.10%1.631.0019.80%-12.20%-7.72%
BDTX
BLACK DIAMOND THERAPEUTICS INC
$81.59M-70.40%-50.40%-68.26%-64.00%0.474.92N/AN/AN/A
NEUP
NEUPHORIA THERAPEUTICS INC
$9.03M-13.40%-10.10%-19.98%307.20%0.322.06100.00%-433.30%-483.45%
INSM
INSMED INC
$13.15B-1,066.20%-51.90%-47.76%-46.40%6.105.4576.40%-251.20%-226.87%
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$1.63B-1,337.40%-15.90%-22.94%-16.90%8.871.2697.00%-41.30%-33.71%
ACTU
ACTUATE THERAPEUTICS INC
$156.25MN/A-389.60%-5,284.79%296.50%88.441.05N/AN/AN/A
ARVN
ARVINAS INC
$591.44M-33.70%-16.70%-23.02%-24.50%0.944.64100.00%-75.50%-75.28%
IKT
INHIBIKASE THERAPEUTICS INC
$141.25M-103.60%-89.60%-29.01%-246.70%0.0426.37N/AN/AN/A
PSTV
PLUS THERAPEUTICS INC
$11.20MN/A-170.50%103.77%150.40%-1.740.34100.00%-222.80%-158.89%
ASMB
ASSEMBLY BIOSCIENCES INC
$75.26M-126.90%-35.30%-55.84%-84.50%2.572.42N/AN/AN/A
SION
SIONNA THERAPEUTICS INC
$488.46MN/A-51.90%-35.18%-76.50%-0.1214.49N/AN/AN/A
RADX
RADIOPHARM THERANOSTICS LTD
$28.03M-105.50%-52.50%-50.53%-174.90%0.763.374.00%-2,427.10%-2,381.21%
MREO
MEREO BIOPHARMA GROUP PLC
$365.70M-67.80%-54.50%-69.60%10,076.90%0.255.40N/AN/AN/A
SMMT
SUMMIT THERAPEUTICS INC
$18.15B-83.00%-60.80%-53.99%-73.70%0.1210.16N/AN/AN/A
NRSN
NEUROSENSE THERAPEUTICS LTD
$24.00MN/A-461.70%-395.28%388.00%0.772.21N/AN/AN/A
ORMP
ORAMED PHARMACEUTICALS INC
$87.83M-11.80%-10.80%-10.04%-12.20%0.0725.19N/AN/AN/A
GLPG
GALAPAGOS NV
$1.63B2.60%1.70%1.90%2.00%0.439.9787.40%26.90%26.22%
NRXP
NRX PHARMACEUTICALS INC
$32.65MN/A-585.50%136.70%220.30%-1.160.15N/AN/AN/A
ATRA
ATARA BIOTHERAPEUTICS INC
$36.15MN/A-63.90%317.16%-457.30%-2.120.4883.70%-66.20%-62.66%
GNLX
GENELUX CORP
$91.01M-106.60%-82.50%-107.39%-118.70%0.324.57100.00%-373,362.50%-373,362.50%
IFRX
INFLARX NV
$62.91M-60.70%-51.80%-74.43%-83.40%0.245.06-1,900.80%-27,785.00%-27,769.42%
SXTP
60 DEGREES PHARMACEUTICALS INC
$4.65M-166.00%-130.30%-193.53%-291.20%0.453.2543.50%-1,237.30%-1,165.19%
OABI
OMNIAB INC
$218.62M-21.10%-18.40%-23.00%-77.70%0.134.52100.00%-235.10%-270.59%
RAPP
RAPPORT THERAPEUTICS INC
$370.44M-33.80%-26.10%-25.58%-35.20%0.0335.34N/AN/AN/A
FATE
FATE THERAPEUTICS INC
$127.20M-49.50%-36.60%-46.31%-37.60%0.387.58100.00%-1,366.50%-1,366.46%
BPMC
BLUEPRINT MEDICINES CORP
$5.41B-21.60%-5.80%-4.10%-3.00%2.952.8596.00%-13.20%-7.41%
TARA
PROTARA THERAPEUTICS INC
$143.39M-44.70%-40.10%-26.16%-229.80%0.0915.71N/AN/AN/A
ANTX
AN2 THERAPEUTICS INC
$37.92M-54.20%-48.90%-62.70%-75.40%0.138.43N/AN/AN/A
VRDN
VIRIDIAN THERAPEUTICS INC
$1.07B-43.30%-39.50%-38.43%-49.40%0.1115.43100.00%-89,387.10%-88,378.48%
MGNX
MACROGENICS INC
$79.49M-66.90%-27.50%-31.49%-72.10%1.263.9291.80%-44.70%-43.28%
RNAC
CARTESIAN THERAPEUTICS INC
$272.02MN/A-19.80%-18.72%-44.40%-64.969.43100.00%-199.00%-198.23%
SWTX
SPRINGWORKS THERAPEUTICS INC
$2.84B-48.30%-41.80%-52.97%-55.80%0.223.8193.40%-134.70%-134.73%
AVXL
ANAVEX LIFE SCIENCES CORP
$761.32M-37.50%-34.10%-41.99%529.50%0.129.45N/AN/AN/A
DNLI
DENALI THERAPEUTICS INC
$1.85B-31.40%-28.60%-33.23%-31.60%0.128.46N/AN/AN/A
IOVA
IOVANCE BIOTHERAPEUTICS INC
$1.00B-50.80%-39.90%-47.58%-84.50%0.283.7424.40%-226.80%-228.56%
SLS
SELLAS LIFE SCIENCES GROUP INC
$119.01M-325.50%-144.50%-311.24%432.20%1.051.72N/AN/AN/A
ONVO
ORGANOVO HOLDINGS INC
$2.50M-346.30%-187.50%-1,364.72%-567.00%9.560.7295.90%-10,151.60%-10,145.90%
SGMO
SANGAMO THERAPEUTICS INC
$158.65M-275.30%-90.10%-175.73%-184.00%3.461.13100.00%-169.40%-169.74%
IMCR
IMMUNOCORE HOLDINGS PLC
$1.42B-14.00%-5.00%-4.28%-4.80%1.804.3899.10%-16.50%-10.99%
BRTX
BIORESTORATIVE THERAPIES INC
$13.13M-82.00%-59.00%-105.25%-99.80%0.442.9793.00%-2,239.20%-2,239.25%
ITRM
ITERUM THERAPEUTICS PLC
$37.35MN/A-105.10%-81.56%-139.80%-11.931.41N/AN/AN/A
WHWK
WHITEHAWK THERAPEUTICS INC
$73.45M-87.70%-69.10%-119.33%-176.90%0.343.5988.40%-245.10%-244.53%
ACIU
AC IMMUNE SA
$148.61M-39.90%-23.10%-39.04%-101.70%1.061.71100.00%-186.40%-185.95%
UNCY
UNICYCIVE THERAPEUTICS INC
$71.82MN/A-90.40%-485.67%257.30%3.261.28N/AN/AN/A
HURA
TUHURA BIOSCIENCES INC
$181.27M-348.90%-240.00%-119.86%42,031.10%0.373.68N/AN/AN/A
TIL
INSTIL BIO INC
$100.86M-39.70%-26.10%-25.48%-18.60%0.5615.76N/AN/AN/A
NRIX
NURIX THERAPEUTICS INC
$780.65M-47.50%-36.10%-39.66%-50.10%0.286.26100.00%-369.40%-369.08%
PGEN
PRECIGEN INC
$408.72M-215.70%-115.60%-103.45%-374.10%2.044.76-8.70%-3,216.20%-3,261.71%
SEPN
SEPTERNA INC
$262.21M-37.60%-24.40%-16.29%-52.20%0.0927.77100.00%-6,678.90%-6,725.21%
PRTA
PROTHENA CORP PUBLIC LTD CO
$495.21M-23.20%-20.30%-25.86%-302.50%0.1210.01100.00%-90.50%-95.39%
ALXO
ALX ONCOLOGY HOLDINGS INC
$29.36M-94.00%-70.90%-102.98%-86.60%0.307.26N/AN/AN/A
TECX
TECTONIC THERAPEUTIC INC
$317.64M-42.50%-38.20%-40.96%1,245.40%0.0912.65N/AN/AN/A
PRLD
PRELUDE THERAPEUTICS INC
$44.68M-74.70%-60.30%-84.85%-69.20%0.345.30N/AN/AN/A
QTTB
Q32 BIO INC
$25.86M-179.70%-40.30%-62.89%-228.90%15.274.97N/AN/AN/A
JAGX
JAGUAR HEALTH INC
$3.71M-309.20%-67.30%-113.46%-92.70%6.101.6383.30%-329.30%-327.32%
NAMS
NEWAMSTERDAM PHARMA CO NV
$1.79B-49.90%-43.20%-31.89%797.60%0.148.08100.00%-530.30%-530.25%
ACRV
ACRIVON THERAPEUTICS INC
$56.75M-46.20%-42.30%-44.91%-56.40%0.1110.55N/AN/AN/A
AARD
AARDVARK THERAPEUTICS INC
$151.87MN/A-46.80%-28.37%-364.40%-0.1015.05N/AN/AN/A
COYA
COYA THERAPEUTICS INC
$87.97M-42.70%-37.90%-38.50%-6,359.70%0.1211.59100.00%-418.70%-438.96%
TSHA
TAYSHA GENE THERAPIES INC
$254.20M-110.60%-51.50%-66.50%-179.50%1.245.42100.00%-1,071.60%-1,070.39%
IMMP
IMMUTEP LTD
$224.16M-30.50%-28.70%-25.32%-88.10%0.0618.86100.00%-398.60%-398.29%
AVBP
ARRIVENT BIOPHARMA INC
$617.05M-28.00%-26.70%-31.24%-181.30%0.0713.14N/AN/AN/A
FBIO
FORTRESS BIOTECH INC
$45.19M-263.60%-38.40%-44.16%-58.00%6.421.2763.80%-96.90%-55.76%
ELVN
ENLIVEN THERAPEUTICS INC
$810.04M-29.20%-27.40%-28.66%-47.40%0.0519.99N/AN/AN/A
CRSP
CRISPR THERAPEUTICS AG
$3.24B-18.50%-15.80%-16.83%-18.10%0.1622.07100.00%-981.50%-971.93%
VIR
VIR BIOTECHNOLOGY INC
$754.29M-38.90%-32.80%-40.89%-40.80%0.228.7198.90%-703.40%-704.95%
ICU
SEASTAR MEDICAL HOLDING CORP
$10.90MN/A-485.60%1,126.11%658.40%-3.130.55100.00%-18,392.60%-18,209.63%
BTAI
BIOXCEL THERAPEUTICS INC
$9.55MN/A-101.50%-276.13%-52.30%-1.411.685.40%-2,630.10%-1,962.49%
AUTL
AUTOLUS THERAPEUTICS PLC
$380.56M-43.80%-26.20%-29.06%-42.60%0.8310.88-12.50%-2,180.50%-2,073.52%
IMNM
IMMUNOME INC
$687.78M-125.30%-105.30%-157.56%-520.50%0.334.08100.00%-3,240.40%-3,240.38%
GERN
GERON CORP
$808.87M-57.00%-35.40%-30.88%-40.20%1.125.5698.40%-226.70%-202.70%
OCUL
OCULAR THERAPEUTIX INC
$1.16B-53.30%-38.60%-43.19%-178.10%0.4510.6691.20%-303.70%-282.36%

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

1. Protalix Biotherapeutics (NYSEMKT:PLX)


Protalix Biotherapeutics (NYSEMKT:PLX) is the #1 top biotech stock out of 664 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Protalix Biotherapeutics (NYSEMKT:PLX) is: Value: B, Growth: A, Momentum: B, Sentiment: A, Safety: C, Financials: B, and AI: C.

Protalix Biotherapeutics (NYSEMKT:PLX) has a Due Diligence Score of 23, which is -1 points lower than the biotech industry average of 24. Although this number is below the industry average, our proven quant model rates PLX as a "A".

PLX passed 7 out of 33 due diligence checks and has weak fundamentals. Protalix Biotherapeutics has seen its stock return 126.96% over the past year, overperforming other biotech stocks by 206 percentage points.

Protalix Biotherapeutics has an average 1 year price target of $15.00, an upside of 474.71% from Protalix Biotherapeutics's current stock price of $2.61.

Protalix Biotherapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Protalix Biotherapeutics, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Aurinia Pharmaceuticals (NASDAQ:AUPH)


Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #2 top biotech stock out of 664 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 57, which is 33 points higher than the biotech industry average of 24.

AUPH passed 19 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 57.84% over the past year, overperforming other biotech stocks by 136 percentage points.

3. Rigel Pharmaceuticals (NASDAQ:RIGL)


Rigel Pharmaceuticals (NASDAQ:RIGL) is the #3 top biotech stock out of 664 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Rigel Pharmaceuticals (NASDAQ:RIGL) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: D, Financials: B, and AI: C.

Rigel Pharmaceuticals (NASDAQ:RIGL) has a Due Diligence Score of 52, which is 28 points higher than the biotech industry average of 24.

RIGL passed 17 out of 33 due diligence checks and has strong fundamentals. Rigel Pharmaceuticals has seen its stock return 51.8% over the past year, overperforming other biotech stocks by 130 percentage points.

Rigel Pharmaceuticals has an average 1 year price target of $36.80, an upside of 118.4% from Rigel Pharmaceuticals's current stock price of $16.85.

Rigel Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Rigel Pharmaceuticals, 20% have issued a Strong Buy rating, 20% have issued a Buy, 60% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Dominari Holdings (NASDAQ:DOMH)


Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 8.02%, which is 6 percentage points higher than the biotech industry average of 2.16%.

Dominari Holdings's dividend payout ratio of -13.4% indicates that its high dividend yield might not be sustainable for the long-term.

2. Novo Nordisk (Ozempic) (NYSE:NVO)


Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.78%, which is 1 percentage points higher than the biotech industry average of 2.16%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.5% indicates that its dividend yield is sustainable for the long-term.

3. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.32%, which is -1 percentage points lower than the biotech industry average of 2.16%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 43.8% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.44% in the last day, and up 7.32% over the last week. Channel Therapeutics was the among the top gainers in the biotechnology industry, gaining 46.61% yesterday.

Channel Therapeutics shares are trading higher after the company announced that it will combine with Ligand Subsidiary Pelthos Therapeutics to create a pain medicines focused entity.

What are the most undervalued biotech stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

1. Puma Biotechnology (NASDAQ:PBYI)


Puma Biotechnology (NASDAQ:PBYI) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -44.68% in the past year. It has overperformed other stocks in the biotech industry by 34 percentage points.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -2.5% in the past year. It has overperformed other stocks in the biotech industry by 76 percentage points.

3. Jazz Pharmaceuticals (NASDAQ:JAZZ)


Jazz Pharmaceuticals (NASDAQ:JAZZ) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Jazz Pharmaceuticals has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Jazz Pharmaceuticals's stock has dropped -4.03% in the past year. It has overperformed other stocks in the biotech industry by 75 percentage points.

Are biotech stocks a good buy now?

55.56% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 119.43% over the next year.

1.96% of biotech stocks have a Zen Rating of A (Strong Buy), 4.36% of biotech stocks are rated B (Buy), 40.74% are rated C (Hold), 36.38% are rated D (Sell), and 16.56% are rated F (Strong Sell).

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is -177.72x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.